BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase I
NeuralStem Inc. ALS Investigator Presents Long-Term Follow Up Phase I Data 9/22/2014
Promedior Announces Presentation Of Retrospective Quantitative Imaging Analysis Of Phase 1b Data In Idiopathic Pulmonary Fibrosis 9/22/2014
Pressure BioSciences, Inc. (BBII) Announces Completion Of The First Phase Of Its Commercialization Plan For The Barozyme HT48, The Company's Recently Released High Throughput PCT-Based Instrument System 9/19/2014
Capricor Therapeutics, Inc. Presents Safety And Preliminary Efficacy Results From ALLSTAR Phase I Clinical Trial At TCT 2014 9/18/2014
SWOG To Resume Clinical Trial Of Halozyme Therapeutics, Inc. (HALO)'s PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 9/18/2014
Concert Pharmaceuticals, Inc. (CNCE) Announces Initiation Of CTP-730 Phase 1 Clinical Trial Under Celgene (CELG) Collaboration 9/17/2014
Experimental Northwest Biotherapeutics (NWBO) Drug Gets First Slot Under UK Early Access Scheme 9/16/2014
First European Patients Enrolled In QT QT Vascular's ENDURE Trial 9/16/2014
Virology Publishes Genocea Biosciences HSV-2 Antigen Discovery Paper 9/16/2014
TapImmune Inc. (TPIV) Releases Positive Interim Data On Phase I Clinical Trial Of Folate Receptor Alpha Antigens In Ovarian And Breast Cancer 9/16/2014
Cleveland Biolabs Inc. (CBLI) Announces Approval To Start Phase 1 Study For Hematopoietic Stem Cell Mobilizer CBLB612 In Russian Federation 9/16/2014
DNAtrix, Inc. Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 9/16/2014
Hemispherx Biopharma (HEB)' Drug Ampligen Plus Intranasal Seasonal Influenza Vaccine Induces Cross-Reactive Antibody Formation Against Avian H5N1 And H7N9 Influenza HA In Humans 9/15/2014
Ultragenyx Pharmaceuticals (RARE) Announces Positive Results From A Long-Term Phase 1/2 Study Of KRN23 In Adult Patients With X-Linked Hypophosphatemia 9/15/2014
MEDIPOST America Clears Phase 1/2 IND For The U.S. Clinical Trial On Stem Cell Drug For Lung 9/15/2014
Alios BioPharma Presents Data On Its Anti-HCV Nucleotide AL-335 At Special Conference On Hepatitis C 9/15/2014
Kolltan Pharmaceuticals Inc. Cancer Study Results For KTN3379, Targeting ErbB3, Support Evaluating Combinations With Targeted Therapies 9/15/2014
QLT Inc. (QLTI) Announces Positive Final Results From Phase 1b Retreatment Trial With Oral Synthetic Cis-Retinoid (QLT091001) In Subjects With LCA Or RP Due To Mutations In RPE65 Or LRAT 9/12/2014
to-BBB Announces Positive Data From Phase 1 Clinical Study 9/12/2014
Synthetic Biologics, Inc. (SYN) Receives Orphan Drug Designation For SYN-005 Treatment For Whooping Cough (Pertussis) 9/11/2014
G1 Therapeutics Initiates Phase 1 Clinical Trial Of G1T28-1 9/11/2014
EMD Group (EMD Millipore (Massachusetts)) Presents New Data on Rebif ® (Interferon beta-1a) And Multiple Sclerosis Pipeline At Joint ACTRIMS-ECTRIMS Meeting In Boston 9/10/2014
Cellular Biomedicine Group (CBMG) Completes Twelve-Month Follow-Up Of Patients From Phase 1/2a Clinical Trial For Rejoin™ Therapy For Knee Osteoarthritis 9/10/2014
Lipocine Inc. (LPCN) Announces First Patient Dosed In Phase 1 Study In Pregnant Women Of LPCN 1107, Potentially The First Oral Product For The Prevention Of Preterm Birth 9/9/2014
Seres Health Presents Final Data For Study Of SER-109 In Recurrent Clostridium Difficile Infection At ICAAC 2014 Conference 9/9/2014
Positive Phase 1a Outcome For Memogain® 9/9/2014
CytRx Corporation (CYTR) Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas 9/9/2014
Redwood City's OncoMed Pharmaceuticals, Inc. (OMED) Moves Forward On Drug Trials Halted Due To Side Effects 9/8/2014
United Therapeutics Corporation (UTHR) Advances To Second Cohort In Phase I Trial Of Pluristem Therapeutics (PSTI)'s PLX-PAD Cells For Treatment Of Pulmonary Arterial Hypertension 9/8/2014
Sangamo BioSciences, Inc. (SGMO) Announces Presentation At ICAAC Of New Clinical Data Demonstrating Sustained Functional Control Of Viremia In Multiple HIV-Infected Subjects Treated With SB-728-T 9/8/2014
GenSpera Presents Mipsagargin (G-202) HCC Clinical Trial Update At 8th International Liver Cancer Association Conference 9/8/2014
KemPharm, Inc. Advances KP201 Clinical Program With Initiation Of Human Abuse Liability And Human Gastrointestinal Motility Trials 9/8/2014
Shionogi & Co., Ltd. Presents Pre-Clinical And Phase I Results For S-649266, A Novel Siderophore Cephalosporine Antibiotic With Potential To Treat Multidrug-Resistant Gram-Negative Pathogens 9/8/2014
Genocea Biosciences Presents Phase 1 Immunology Data For Novel Pneumoccocus Vaccine At ICAAC 9/8/2014
Celsion Corporation (CLSN) Reports Consolidated Duke University And Celsion's DIGNITY Study Clinical Data On Thermodox® In Recurrent Chest Wall Breast Cancer Published In The International Journal Of Hyperthermia 9/5/2014
Johnson & Johnson (JNJ) Jumps Into The Ebola Race; To Start Human Trials In Early 2015 9/4/2014
VG Life Sciences, Inc. (VGLS) Progress Update Phase I Cancer Study 9/4/2014
Mirati Therapeutics  (MRTX) Initiates Phase 1 Study Of MGCD516 For Non-Small Cell Lung Cancer And Other Advanced Solid Tumors 9/4/2014
Novira Therapeutics Announces Successful Completion Of Phase 1a Clinical Study Of NVR-1221 And Commencement Of Phase 1b Clinical Studies 9/4/2014
Cleave Biosciences Initiates Phase 1 Clinical Trial Of CB-5083 In Patients With Multiple Myeloma 9/4/2014
FDA Give NewLink Genetics Approval To Proceed To Phase 1 Clinical Studies Of Their Ebola Vaccine 9/4/2014
Ultragenyx Pharmaceuticals (RARE) Announces Positive Interim Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7 9/3/2014
BioLineRx Ltd. Doses First Patient For BL-8040’s Second Indication As Novel Stem Cell Mobilization Treatment 9/3/2014
Sabin Vaccine Institute Release: Phase 1 Clinical Trial Of Human Hookworm Vaccine Successfully Completed 9/3/2014
Halozyme Therapeutics, Inc. (HALO)'s PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation 9/3/2014
Actinium Pharmaceuticals, Inc. (ATNM.OB) Files Orphan Drug Application For Use Of Actimab-A In The Treatment Of Newly Diagnosed Acute Myeloid Leukemia In Elderly Patients 9/3/2014
Soligenix (SNGX) Announces Positive Survival Results With Heat Stable Ricin Toxin Vaccine 9/3/2014
Synthetic Biologics, Inc. (SYN) To Initiate Clinical Trials Of SYN-004 In 4Q 2014 To Prevent Potentially Deadly C. difficile Infections 9/3/2014
Catalyst Pharmaceutical Partners, Inc. (CPRX) Initiates Phase 1(B) Safety And Tolerance Study For CPP-115 9/2/2014
Capstone Therapeutics (CAPS) Announces Phase 1a Results For AEM-28 Showing Safety And Biomarker Efficacy Signals 9/2/2014
Boston Strategics Corporation Initiates A Phase 1 Clinical Trial Of The Anti-Cancer Agent "FF-10501" For FUJIFILM In Patients With Advanced Hematologic Malignancies 9/2/2014
F2G Ltd, The UK-Based Antifungal Drug Discovery And Development Company, Today Announces Commencement Of A Phase 1 Single Ascending Dose Study Of A Novel Antifungal Agent, F901318. 9/2/2014
OncoMed Pharmaceuticals, Inc. (OMED) Says FDA Lifts Partial Hold On Cancer Drug Trials For Vantictumab 8/29/2014
Senesco Technologies, Inc. (SNT) Closes Enrollment In Its Phase 1b/2a SNS01-T Study 8/29/2014
GlaxoSmithKline (GSK)'s Ebola Vaccine To Be Tested For Safety In Humans As Early As Next Week 8/28/2014
Immunotech Laboratories Announces Successful Completion Of Phase 1 And Phase 2 Field Trials Of The Company’s Patented Treatment Of The HIV/AIDS And Hepatitis C Viruses 8/28/2014
Telik, Inc. (TELK) Reports Progress Toward Multiple Early Stage Milestones In The Development Of A Novel Antibody-Based Therapeutic Agent For Gastrointestinal Cancers 8/28/2014
Synthetic Biologics, Inc. (SYN) And Fujifilm Diosynth Biotechnologies Announce Significant Improvement In API Manufacturing Of SYN-004 For The Prevention Of C. Difficile 8/28/2014
Innate Pharma (IPH.PA ) : Orphan Drug Designation In The European Union For Iph4102 8/27/2014
Asterias Biotherapeutics Receives U.S. FDA Clearance To Initiate Phase 1/2a Clinical Trial Of AST-OPC1 In Patients With Cervical Complete Spinal Cord Injury 8/27/2014
BioTime (BTX) Subsidiary Asterias Biotherapeutics Receives FDA Clearance To Initiate Phase 1/2a Clinical Trial Of AST-OPC1 In Patients With Cervical Complete Spinal Cord Injury 8/27/2014
SoCal's Kite Pharma, Inc. (KITE) Shares Fly High On Non-Hodgkin's Lymphoma Drug Study Results 8/26/2014
Ruthigen Receives Recommendation From Data Monitoring Committee To Initiate Phase 1/2 Human Clinical Trial Of RUT58-60 8/26/2014
Profil Institute for Clinical Research, Inc. Reaches Milestone In Early Phase Clinical Research For Diabetes 8/26/2014
Alkermes plc (ALKS) Announces Initiation Of Phase 1 Clinical Study Of ALKS 7106 For Treatment Of Pain 8/26/2014
BeiGene Co.,Ltd Enrolls First Patient In Phase 1 Study Of BGB-3111 8/26/2014
North Carolina's BioKier, Inc. Takes A Shot At A New Kind Of Diabetes Drug 8/25/2014
Oncothyreon Inc. (ONTY)'s Lung Cancer Drug EMR 63325-009 Misses Primary Endpoint In Phase 1 Study 8/20/2014
NuSirt Biopharma Launches First Clinical Trial 8/20/2014
KalVista Pharmaceuticals Announces Start Of Clinical Development For Novel Treatment For Diabetic Macular Edema 8/20/2014
22nd Annual Susan G. Komen Phoenix Race For The Cure® 2014 Moves To Downtown Phoenix 8/20/2014
Anavex Life Sciences Corp. (AVXL.OB) Reports That Antidepressant Fluvoxamine Reduces Stress Through Sigma-1 Receptor 8/19/2014
DelMar Pharmaceuticals Provides Update On Glioblastoma Clinical Trial And Results Of Warrant Tender Offer 8/19/2014
Data Published By Researchers From The Scripps Research Institute Demonstrate Potential For MYC Inhibitor Licensed By Sorrento Therapeutics, Inc. 8/18/2014
MonoSolRx LLC Launches Clinical Study Of MSRX-110 Oral Film For Testosterone Replacement 8/18/2014
TG Therapeutics, Inc. (MHA) Announces Novel "Chemo-Free" Triple Therapy Combination Clinical Study For Patients With Chronic Lymphocytic Leukemia And Other B-Cell Malignancies 8/15/2014
Tekmira Pharmaceuticals Corporation (TKMR)'s Experimental Ebola Drug May Never Reach Africa 8/14/2014
Nuvilex (NVLX) Announces Publication Of Combined Results Of The Initial Phase 1/2 Clinical Trial And A Second Phase 2 Clinical Trial Of The Cell-In-A-Box® Plus Ifosfamide Combination In Patients With Advanced, Inoperable Pancreatic Cancer 8/14/2014
Alexza Pharmaceuticals, Inc. (ALXA) Provides An Update On The Five Post-EMA Approval Studies For ADASUVE® 8/14/2014
Publication By KaloBios Pharmaceuticals, Inc. (KBIO) And Collaborators Shows EphA3 As Target For Highly Selective Anticancer Therapy 8/14/2014
Agios Pharmaceuticals (AGIO) Announces The U.S. FDA Grants Fast Track Designation To AG-221 For Treatment Of Patients With Acute Myelogenous Leukemia That Harbor An IDH2 Mutation 8/13/2014
Epizyme (EPZM) Presents Pre-Clinical Data And Early Clinical Observations From Ongoing Phase 1 Trial Of EZH2 Inhibitor EPZ-6438 (E7438) At American Society of Hematology Meeting On Lymphoma Biology 8/13/2014
Enzymotec Announces Initiation Of A Clinical Study On Autism Spectrum Disorder 8/12/2014
Seattle Genetics, Inc. (SGEN) Initiates Phase 1 Clinical Trial Of Antibody-Drug Conjugate SGN-CD70A For Non-Hodgkin Lymphoma And Renal Cell Carcinoma 8/12/2014
Flex Pharma Announces Positive Results From Human Clinical Studies 8/12/2014
GlaxoSmithKline (GSK) Will Take Its Shot At Ebola Later This Year 8/12/2014
Tekmira Pharmaceuticals Corporation (TKMR) Shares Go Bonkers As Ebola Drug May Be Used On Infected Patients: FDA 8/11/2014
Merrimack Pharmaceuticals Inc. (MACK) Announces Initiation Of HERMIONE, A Randomized Trial Of MM-302 In Patients With Advanced HER2-Positive Breast Cancer To Support Application For Accelerated Approval 8/11/2014
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Reports Top-Line Results Showing Equivalent Exposures After Oral and Intravenous Delafloxacin Administration 8/11/2014
PTC Therapeutics, Inc. (PTCT) Release: Orally Delivered Compounds, Which Selectively Modify RNA Splicing Prevent Deficits In Mouse Models Of Spinal Muscular Atrophy 8/8/2014
Soligenix (SNGX) Advances Development Of A Heat Stable Rapidly Acting Anthrax Vaccine VeloThrax™ 8/7/2014
Oramed Pharmaceuticals Inc. (ORMP) Reports Last Patient Out In Phase Iia Trial For ORMD-0801 In Type 1 Diabetes 8/7/2014
Cellceutix (CTIX) Anti-Psoriasis Drug Prurisol Meets Primary Endpoint Of Clinical Trial 8/7/2014
Enanta Pharmaceuticals, Inc.’ HCV NS5A Inhibitor EDP-239 Advances Into Combination Studies With Alisporivir (DEB025) 8/7/2014
Alnylam Pharmaceuticals (ALNY) Receives Orphan Drug Designations In The European Union For ALN-AT3, An Rnai Therapeutic In Development For The Treatment Of Hemophilia 8/7/2014
TapImmune Inc. (TPIV)'s New Clinical Trial In Advanced Stage Ovarian Cancer Expands The Use Of Folate Receptor Alpha Peptide Antigens 8/7/2014
MD Anderson Cancer Center Postdoc Faked Results Of Novartis AG (NVS) Brain Tumor Study 8/7/2014
Generex Biotechnology Corporation (GNBT) Announces Publication Of AE37 Prostate Cancer Vaccine Study 8/6/2014
Trevena, Inc. (TRVN) Initiates Phase 1 Multiple Ascending Dose Study Of TRV734 For Acute And Chronic Pain 8/6/2014
Synthetic Biologics, Inc. (SYN) On Track To Initiate Clinical Program For SYN-004 To Protect Against C. difficile 8/5/2014
Moerae Matrix Initiates Phase 1 Clinical Trial Of MMI-0100, A First-In-Class Inhibitor Of MK2, For Treatment Of Idiopathic Pulmonary Fibrosis 8/5/2014
Caris Life Sciences Release: Caris Molecular Intelligence™ Identifies Key Biomarkers Of Clinical Benefit And Resistance To Chemotherapy Through Multi-Technology Tumor Profiling 8/5/2014
NovImmune SA Reports Successful Completion Of Phase I Trial For NI-0101 8/5/2014
AbbVie (ABBV)'s Brain Tumor Drug Gets U.S., EU Orphan Designation 8/4/2014
Prothena Corporation plc Release: Initiation Of Multiple Ascending Dose Phase 1 Study Of PRX002 In Patients With Parkinson's Disease 8/1/2014
AstraZeneca PLC (AZN) Steps Up Push Into Cancer Immunotherapy, Falls Behind Rivals Such As Bristol-Myers Squibb Company (BMY), Merck & Co., Inc. (MRK), And Roche (RHHBY) 7/31/2014
AFFiRiS AG Presents Phase I Data On A First-Of-Its-Kind Treatment With Support From The Michael J. Fox Foundation 7/31/2014
Cara Therapeutics, Inc. (CARA) Initiates Human Abuse Liability Trial Of CR845 7/31/2014
AFFiRiS AG Release: First Clinical Data Of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 7/31/2014
BioTime (BTX) Subsidiary OncoCyte Corporation Expands Clinical Development Of Bladder Cancer Diagnostic By Initiating A Large Multi-Site Clinical Trial 7/31/2014
AtheroNova Inc. (AHRO.OB) Announces Milestone With Initiation Of Phase 1b Clinical Trial Of AHRO-001 7/30/2014
Galectin Therapeutics Issues Statement on GR-MD-02 Development Program 7/30/2014
Inergetics, Inc. Completes Phase I Development Of Its Therapeutic CBD Line Of Products 7/29/2014
Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 7/28/2014
Galectin Therapeutics To Host Webcast To Discuss Findings From Cohort 2 Of Phase 1 Clinical Trial Of GR-MD-02 In Fatty Liver Disease With Advanced Fibrosis 7/25/2014
Bavarian Nordic (BAVA.CO) Announces First Patient Treated In A Phase 1 Study Of MVA-BN® Brachyury In Advanced Cancer 7/24/2014
Advanced Biologics Publishes Additional Osteoamp® Abstracts In The Bone And Joint Journal 7/24/2014
Media Advisory: AFFiRiS AG Presents Early Clinical Data On A First-Of-Its-Kind Parkinson's Disease Vaccine 7/24/2014
Amunix, Inc. And PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates In Vivo Studies In American Chemical Society's Journal 7/24/2014
Biosceptre Announces Positive Phase I Results For BIL-010t To Treat Basal Cell Carcinoma 7/23/2014
Dyax Corp. (DYAX) Announces Publication Of Scientific Data For DX-2930 In Peer-Reviewed Journals 7/23/2014
Ligand Pharmaceuticals Inc. (LGND) Partner SAGE Therapeutics Receives Fast Track Designation For Captisol-enabled SAGE-547 To Treat Status Epilepticus 7/23/2014
Dompe Announces The FDA Has Granted Orphan Drug Designation To Its rhNGF-Based Treatment For Neurotrophic Keratitis 7/23/2014
SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus 7/22/2014
MYOS (MYOS) Reports Positive Top-Line Clinical Study Results of Fortetropin's Muscle Building Activity in Male Subjects 7/22/2014
Jazz Pharmaceuticals plc (JAZZ) And Concert Pharmaceuticals, Inc. (CNCE) Provide A Phase 1 Clinical Trial Update On JZP-386 7/22/2014
Galectin Therapeutics Announces First Patient Dosed In Cohort 1 Of Phase 1B Clinical Trial Of GR-MD-02 In Combination With Ipilimumab In Metastatic Melanoma 7/22/2014
Genocea Biosciences HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses In Vaccinated Subjects 7/22/2014
ERYtech Pharma Announces Enrollment Of First Patient In Phase I/II Study Of ERY-ASP In Acute Lymphoblastic Leukemia In The United States 7/22/2014
ZIOPHARM, Inc. Announces Expansion Of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon And Clinical Program Update 7/22/2014
Regulus Therapeutics, Inc. Receives Orphan Drug Designation For RG-012, A microRNA Therapeutic For The Treatment Of Alport Syndrome 7/21/2014
Ignyta (RXDX) Announces Initiation Of STARTRK-1 Global Phase I/II Clinical Trial Of RXDX-101 7/21/2014
Synthetic Biologics, Inc. (SYN)' Academic Collaborator To Present Novel Monoclonal Antibody Combination For Treating Whooping Cough (Pertussis) At Gordon Research Conference 7/21/2014
Tekmira Pharmaceuticals Corporation (TKMR) Provides Update on TKM-Ebola Phase I Clinical Hold 7/21/2014
Tekmira Pharmaceuticals Corporation (TKMR) Provides Update On TKM-Ebola Phase I Clinical Hold 7/21/2014
"MetaMax" LLC Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment Of First Patients In Phase 1/2a Clinical Trial Of Its Lead Anticancer Drug MM-D37K 7/21/2014
Can-Fite BioPharma (CFBI) CEO To Deliver Scientific Presentation And Serve On Expert Panel At Purines 2014 In Bonn, Germany On July 23-27, 2014 7/21/2014
Rexahn Pharmaceuticals, Inc. (RNN) Provides Update On Phase I Supinoxin Trial In Cancer Patients With Solid Tumors 7/18/2014
FDA Lifts Partial Clinical Hold For Concert Pharmaceuticals, Inc. (CNCE)'s CTP-354 7/17/2014
Nuvilex (NVLX) And Austrianova Announce Results Of Clinical Trial In Dogs With Mammary Tumors Treated With Cell-In-A-Box® Plus Cyclophosphamide 7/17/2014
Silk Road Medical Completes Enrollment In The ROADSTER Clinical Trial For Carotid Artery Disease 7/17/2014
Alkermes plc (ALKS) Announces Initiation Of Phase 1 Clinical Study Of ALKS 8700 For Treatment Of Multiple Sclerosis 7/17/2014
Dipexium Pharmaceuticals (DPRX) Announces Successful Completion Of Phase 1 Skin Irritation Trial Of Locilex® 7/17/2014
Juvenile Diabetes Research Foundation Partner ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces Key Project Milestone To Advance Innovative Encapsulated Cell Replacement Therapy Product For Type 1 Diabetes 7/17/2014
Ruthigen Treats First Human Subjects In Clinical Trial For RUT58-60 7/17/2014
Capricor Therapeutics, Inc. Announces Encouraging Results From Phase1 ALLSTAR Trial; Phase 2 Trial Underway 7/16/2014
Northwest Biotherapeutics (NWBO) Announces Completion Of DCVax®-Direct Phase I Trial Recruitment 7/16/2014
BioLineRx Ltd. Announces Results From Phase 1/2 Study For Celiac Treatment 7/16/2014
ChromaDex, Inc. Initiates First Human Clinical Study To Confirm ChromaDex's NIAGEN™ Nicotinamide Riboside Will Increase NAD+ 7/16/2014
ImQuest Pharmaceuticals, Inc. Receives FDA Approval To Initiate Clinical Trials Of A Vaginal Gel For The Prevention Of HIV Transmission To Women 7/16/2014
Egalet Reports Positive Top-Line Results From Category 1 Abuse Deterrence Studies Demonstrating Egalet-001 Resists Physical And Chemical Manipulation 7/15/2014
Helix Biopharma (CC:HBP) Initiates Enrollment For Ninth Cohort In Polish Phase I/II Clinical Study Of Its Lung Cancer Drug Candidate L-DOS47 7/15/2014
Novartis AG (NVS) To Test Alzheimer's Drugs In Patients Without Symptoms 7/15/2014
Cellceutix (CTIX) Announces Breakthrough In The Formulation Of Its Novel Antibiotic Brilacidin™, Plans Studies To Treat Diabetic Foot Ulcers 7/15/2014
QLT Inc. (QLTI) Announces Publication In The Lancet Of Phase 1b Data For QLT091001 In Leber Congenital Amaurosis Due To LRAT Or RPE65 Mutations 7/14/2014
Trevi Therapeutics Announces Initiation Of A Pivotal Study Of Nalbuphine ER In Uremic Pruritus 7/14/2014
Probiodrug AG Presents Development Overview Of PQ912, Probiodrug’s QC-Inhibitor For Alzheimer’s Disease 7/10/2014
Dezima Pharma Extends Clinical Development Program For Its CETP Inhibitor TA-8995 7/9/2014
Soligenix (SNGX) Announces Combination Vaccine For Ricin And Anthrax Achieves Simultaneous Protection 7/9/2014
Threshold Pharmaceuticals, Inc. (THLD) Announces Initiation Of Dosing With TH-302/Bortezomib (Velcade(R))/Dexamethasone ("TBorD") In Final Stage Of Ongoing Phase 1/2 Trial Of Patients With Relapsed/Refractory Multiple Myeloma 7/9/2014
Novartis AG (NVS) Wins Breakthrough Status For New Leukemia Treatment CTL019 7/8/2014
Cesca Therapeutics Management Provides Regulatory Update On Its Proposed U.S. Pivotal Critical Limb Ischemia Clinical Trial 7/8/2014
Cortice Biosciences Announces Enrollment Of A Phase 1 Clinical Trial Evaluating TPI 287 In Rare Tauopathy Diseases 7/7/2014
GenSpera To Present Ongoing HCC Trial Data At APPLE 2014 Congress July 12th In Taipei 7/7/2014
Reaction Biology Corp. Receives National Institutes of Health (NIH) Grant Award For Epigenetic Database 7/7/2014
BeiGene Co.,Ltd Enrolls First Patient In Phase 1 Study Of BGB-290 7/7/2014
Glenmark Pharmaceuticals's Novel Monoclonal Antibody GBR 830 For Treatment Of Autoimmune Diseases Entering Human Trials 7/3/2014
Akashi Therapeutics Presents Positive Clinical Data On HT-100 In Patients With Duchenne Muscular Dystrophy 7/3/2014
Akashi Therapeutics Receives Fast Track Designation For HT-100 From FDA For The Treatment Of Duchenne Muscular Dystrophy 7/3/2014
Tekmira Pharmaceuticals Corporation (TKMR) Sinks As The FDA Puts Ebola Study On Hold; Stock Down -15.54% At Market Close (July 3, 2014) 7/3/2014
Galapagos NV (GLPG.BR) Initiates Phase 1 Study With GLPG1690, Triggering €6.6 M Milestone In The Alliance With Janssen Pharmaceutica N.V. 7/1/2014
GlycoVaxyn AG Announces The Initiation Of A Phase I Clinical Trial In Collaboration With Janssen Pharmaceutical Inc. For A Vaccine Against Extra-Intestinal Pathogenic Escherichia Coli Causing Urinary Tract Infection 7/1/2014
Genocea Biosciences Announces Positive Top-Line 12-Month Follow-Up Data From Phase 1/2a Clinical Trial For HSV-2 Immunotherapy GEN-003 7/1/2014
Aeolus Pharmaceuticals Inc. (AOLS.OB) Announces Additional Data Demonstrating Efficacy Of AEOL 10150 As A Medical Countermeasure Against Exposure To Nerve Agents, Sulfur Mustard Gas And Nitrogen Mustard Gas 7/1/2014
CritiTech Announces Positive Results From Phase I Trial Of Nanotax® For Intraperitoneal Cancers 7/1/2014
Nora Therapeutics Presents Phase 1 Data On NT100 At The European Society Of Human Reproduction And Embryology Annual Meeting 6/30/2014
Xenetic Biosciences Announces Ongoing Safety Data From Phase 2 Trial Of Erepoxen® 6/30/2014
Anavex Life Sciences Corp. (AVXL.OB) Announces Report Expanding Opportunity For Therapeutic Application Of Anavex Compounds 6/30/2014
Ampio Pharmaceuticals, Inc. (AMPE) Initiates Study of Multiple Injections Of Ampion™ Into The Knees Of Patients With OA Of The Knee To Assess Its Healing And Cartilage Regeneration Effects 6/30/2014
First Patient Enrolled In FDA Phase 1/2a Clinical Trial With Biolight's Controlled-Release Latanoprost Insert For The Treatment Of Glaucoma 6/30/2014
Northwestern Medicine Release: Researchers Seek to Tackle Transplant Tolerance Using Patients' Own T Cells 6/30/2014
Retrophin, Inc. (RTRX) Slumps As Patient On Key Drug Shows High Liver Enzyme Levels 6/27/2014
Antibe Therapeutics Inc. Announces First Human Dose Of ATB-346 In Phase I Clinical Trial 6/27/2014
Boehringer Ingelheim Corporation's Investigational Antidote For Pradaxa® Grabs FDA Breakthrough Therapy Designation 6/26/2014
Targacept, Inc. (TRGT) Initiates Exploratory Study Of TC-6499 In Diabetic Gastroparesis 6/25/2014
Calimmune Approved To Treat Second Group In HIV Stem Cell Gene Modification Study 6/25/2014
Debiopharm And TCG Lifesciences Announce Successful Completion Of First Phase Of Research Collaboration On Discovery Of Novel Antibiotics 6/24/2014
Results Of Phase 1b Clinical Trial Comparing Trevena, Inc. (TRVN)’s TRV130 To Morphine Published In The Journal Pain 6/24/2014
Ultragenyx Pharmaceuticals Announces Results From Phase 1/2 Study Of KRN23 In X-Linked Hypophosphatemia In Adults 6/24/2014
Regado Biosciences, Inc. (RGDO)' REG2 Demonstrates Dose And Concentration-Dependent Suppression Of Thrombin Generation 6/23/2014
Ligand Pharmaceuticals Inc. (LGND) Announces Presentation Of Positive Data From A Phase 1 Study On The Effect Of The SERM Lasofoxifene To Increase Testosterone Levels In Men 6/23/2014
Trevena, Inc. (TRVN) Announces Positive Phase 1 Results For TRV734 For Acute And Chronic Pain 6/23/2014
Clovis Oncology (CLVS) Announces First Patient Enrolled In TIGER2 Study 6/23/2014
Triphase Accelerator Announces Orphan Drug Designation In The European Union For Marizomib For Multiple Myeloma 6/23/2014
Enteris Biopharma Oral Peptide Delivery Technology Enables Key Clinical Milestone For Acute And Chronic Pain Drug 6/20/2014
Northwest Biotherapeutics (NWBO) Biotechnology Industry Organization (BIO) Reaffirms DCVAX®-Direct Clinical Trial Interim Data Announcements 6/20/2014
StemCells Inc. (STEM) Announces Closure Of Enrollment In Phase 1/2 Dry Age-Related Macular Degeneration Trial 6/20/2014
NeoStem, Inc. Announces University of California, San Francisco (UCSF) Presentation Of Phase 1 Results For T Regulatory Cell Immunotherapy For Type 1 Diabetes At American Diabetes Association Annual Meeting 6/19/2014
Aratana Therapeutics (PETX) Initiates And Doses First Patient In Market Development Studies Of AT-005 For Treating Canine T-Cell Lymphoma 6/19/2014
NeuralStem Inc. NSI-189 Select Data To Be Presented At Neuropsychopharmacology Congress 6/19/2014